Sign In
Buy CRMD
$8.23
+0.0600 (+0.734%)
At Close: Jun 03, 2026
CorMedix Therapeutics Announces Leadership and Board Updates
08:05am, Thursday, 08'th Jan 2026
BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thre
CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates
08:00am, Thursday, 08'th Jan 2026
‒ Q4 2025 Unaudited Net Revenue of Approximately $127 million ‒ ‒ FY 2025 Unaudited Pro Forma Net Revenue of Approximately $400 million ‒ ‒ Expects Q4 Adjusted EBITDA of Between $77 million
CorMedix (NASDAQ:CRMD) Director Alan Dunton Sells 20,000 Shares
05:38am, Saturday, 03'rd Jan 2026
CorMedix Inc (NASDAQ: CRMD - Get Free Report) Director Alan Dunton sold 20,000 shares of the firm's stock in a transaction dated Tuesday, December 30th. The stock was sold at an average price of $13.0
CorMedix (NASDAQ:CRMD) Stock Price Down 4.9% – Here’s What Happened
05:08am, Friday, 02'nd Jan 2026
CorMedix Inc (NASDAQ: CRMD - Get Free Report)'s share price fell 4.9% during trading on Wednesday. The company traded as low as $11.80 and last traded at $11.8650. 1,976,410 shares traded hands during
Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath?
10:15am, Friday, 26'th Dec 2025
CRMD's $300M Melinta acquisition adds seven products and helps raise 2025 revenue guidance, but questions remain over easing DefenCath reliance.
Why CorMedix Could be the Biopharma Name to Watch Early in 2026
03:20pm, Tuesday, 23'rd Dec 2025
An often overlooked risk for patients receiving dialysis for kidney failure or related conditions is infection. Unfortunately, infections among dialysis patients are both common and serious, presentin
Joseph Todisco Sells 30,000 Shares of CorMedix (NASDAQ:CRMD) Stock
05:02am, Sunday, 21'st Dec 2025
CorMedix Inc (NASDAQ: CRMD - Get Free Report) CEO Joseph Todisco sold 30,000 shares of the business's stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $12
CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath
08:00am, Thursday, 18'th Dec 2025
BERKELEY HEIGHTS, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thre
CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy?
12:31pm, Wednesday, 17'th Dec 2025
CorMedix's DefenCath sales and Melinta deal raise growth stakes while Puma Biotechnology's Nerlynx-led breast cancer franchise aids growth.
5 High Earnings Yield Value Picks Ahead of Key Economic Reports
08:06am, Tuesday, 16'th Dec 2025
CRMD, CGAU, CMC, COMM and SHIP emerge as high earnings yield value picks as investors eye fundamentals ahead of key jobs and inflation reports.
CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock?
12:01pm, Thursday, 11'th Dec 2025
CorMedix surges on strong DefenCath uptake as sales climb while the Melinta acquisition expands and diversifies its commercial portfolio.
Does CorMedix (CRMD) Have the Potential to Rally 68.74% as Wall Street Analysts Expect?
10:55am, Tuesday, 09'th Dec 2025
The mean of analysts' price targets for CorMedix (CRMD) points to a 68.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
CorMedix (CRMD) Upgraded to Strong Buy: Here's What You Should Know
01:01pm, Monday, 08'th Dec 2025
CorMedix (CRMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Value Stocks to Buy for December 8th
08:21am, Monday, 08'th Dec 2025
GM, CRMD and AER made it to the Zacks Rank #1 (Strong Buy) value stocks list on December 8, 2025.
New Strong Buy Stocks for December 8th
06:31am, Monday, 08'th Dec 2025
VFF, CRMD, AER, GM and FIVE have been added to the Zacks Rank #1 (Strong Buy) List on December 8, 2025.
